CCR2 and neoplasm: Furthermore, to investigate whether blocking CCR2 in xenograft models inhibits the recruitment of MDSCs in OSCC TME, we injected CCR2 antagonist i.p. (3 mg/kg, every other day) into the tumor/stromal coxenografts (Figure 7A) and evaluated the MDSCs by multicolor immunofluorescence staining.